Faeth Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Faeth Therapeutics, Inc. (FTH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $12.85 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.39, a 88.26% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $11.84, a 35.47% increase year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.74, a 8.77% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $9.58, a 59.67% increase year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $13.02, a 412.60% increase from fiscal 2024.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $2.54, a 55.98% decline from fiscal 2023.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $5.77, a 24.77% decline from fiscal 2022.
- Faeth Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $7.67, a 16.45% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.85 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $13.02 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $18.28 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $18.28 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $1.39 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $2.54 10-K · filed 2025-03-28 | |||
| 2024-09-30 | $2.87 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $3.00 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $11.84 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $5.77 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $5.61 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $5.61 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $8.74 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $7.67 10-K · filed 2023-03-29 | |||
| 2022-09-30 | $8.92 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $8.90 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $9.58 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $9.18 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $5.91 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $6.13 10-Q · filed 2021-08-11 | |||
| 2021-03-31 | $6.00 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $119.38 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |